This is the first year ORIC has included a Say on Pay vote, so there is no prior-year result to consider. The CEO's total compensation of $5,567,164 is consistent with market expectations for a CEO at a clinical-stage biotech company with a market cap of approximately $1.1 billion. Pay mix is heavily weighted toward variable compensation — salary of $657,500 represents only about 12% of total pay, with the remainder in equity awards and a performance-based cash bonus, well exceeding the 50-60% variable pay threshold required by policy. The 2025 bonus plan was funded at 120% of target based on measurable clinical and corporate milestones, and ORIC's stock outperformed the XBI — SPDR S&P Biotech ETF benchmark over the past year (+27.8 percentage points), supporting the conclusion that above-target incentive pay was aligned with shareholder outcomes. The company also discloses a clawback policy consistent with post-Dodd-Frank requirements.

KPMG has served as ORIC's auditor since 2018, giving it approximately 8 years of tenure — well below the 25-year threshold that would trigger concern. Non-audit fees (tax fees of $113,000 plus other fees of $1,780 totaling $114,780) represent approximately 14.8% of audit fees of $772,939, comfortably below the 50% threshold that would raise independence concerns. KPMG is a Big 4 firm appropriate for a company of ORIC's size. No material restatements were identified.